She doesn’t know her glucose has already changed.

She is 47, doesn’t feel ill and has no reason to: impaired glucose does not hurt. If she took a test today, the result would put her in a territory that has no name in her health contract or in her employer’s benefit, and that in a few years, if nobody does anything, may end up with a diagnosis, a code and a treatment, though it does not have to: it is a risk, not a destiny. World Diabetes Day, every 14 November, carries this cycle a theme that seems obvious and is not: early action. Obvious, because nobody argues that it is better to act sooner. Not so obvious, because most health systems, and insurance contracts, are designed to pay later, that is, when she is already a patient.
The numbers in the IDF Atlas, in its eleventh edition of 2025, give the scale, and they are modelled estimates for adults aged 20 to 79, not census counts. In 2024, 589 million people were living with diabetes, one in nine, and 252 million of them, 43%, did not know it. Alongside them, 635 million had impaired glucose tolerance and 488 million had impaired fasting glucose, two conditions that overlap and together form the territory where she is today. Health spending attributed to diabetes reached 1.015 trillion dollars, 338% more than 17 years earlier. It is a modelled figure that depends on its assumptions, among them the cost ratio between people with and without diabetes, and it does not equal an avoidable saving; it serves as a declared order of magnitude, not as a budget.
The 2050 projection, 853 million people, is a conditional projection, which incorporates demographic change and does not describe her fate. What early action can move is measured elsewhere: the Diabetes Prevention Program, a trial of 3,234 high-risk people followed for an average of 2.8 years, reduced the incidence of diabetes by 58% with an intensive lifestyle intervention, from 11.0 to 4.8 cases per 100 person-years; about seven people had to be treated for three years to prevent one case. It is a United States trial; its costs do not transfer to Chile as they are.
The greater obstacle for her is not clinical but accounting. Her impaired glucose rarely appears in an insurer’s claims experience or in the coverage of a benefit, and how it is coded and financed in Chile is something each organisation should review in its own catalogues before assuming it is invisible. For the budget five years from now, she is not.
For the organisation that covers her, early action means three decisions: screening, to know how many like her are in the portfolio; funding the intervention that has evidence; and measuring the progression avoided, not the tests performed. None promises a saving; all three make it possible to know whether there was one.
Her diabetes began years before the diagnosis. So did the spending.
Sources: International Diabetes Federation. IDF Diabetes Atlas, 11th edition, 2025. https://diabetesatlas.org/data-by-location/global/ · Full text · IDF. World Diabetes Day 2026–27: Early action on diabetes (04-03-2026). · Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403. · Ministry of Health of Chile (MINSAL), Department of Epidemiology. National Health Survey 2016–2017: first results, November 2017 (section “Suspected diabetes mellitus”: fasting glucose ≥ 126 mg/dl).